Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

American Society of Hematology 2016 annual meeting

American Society of Hematology 2016 annual meeting At the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

American Society of Hematology 2016 annual meeting

Loading next page...
 
/lp/springer-journals/american-society-of-hematology-2016-annual-meeting-a09erKGW9c
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0340-6
Publisher site
See Article on Publisher Site

Abstract

At the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 19, 2017

References